This synergistic effect is consistent with findings in ovarian and palbociclib-resistant, ER-positive breast cancers, where STAT3 inhibitors (e.g., C188-9, napabucasin, and TTI-101) combined with olaparib or other PARP inhibitors have shown enhanced anti-cancer efficacy, including increased apoptosis and reduced tumor growth [39,44]. Here, PARP1 is linked to neoplasm.